by Sue Robbins | Mar 2, 2020 | Miscellaneous
The FDA has approved Voltaren Arthritis Pain for nonprescription, over-the-counter use, according to a press release. Voltaren (diclofenac sodium topical gel 1%, GlaxoSmithKline), a NSAID previously available only with a prescription, is intended for the temporary...
by Sue Robbins | Mar 2, 2020 | Migraine
In the book “Migraine: A History” (Johns Hopkins University Press), medical historian Katherine Foxhall writes of a disabling disease that has been documented going back thousands of years, though the causes of this neurological disorder are still unclear....
by Sue Robbins | Feb 28, 2020 | Migraine
NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant) for the acute treatment of migraine in adults. Nurtec...
by Sue Robbins | Feb 27, 2020 | Migraine
Patients with psoriasis are at increased risk for migraines, according to a research letter published in the Journal of the American Academy of Dermatology. Researchers from the New York University School of Medicine examined data obtained from the 2003-2004 National...
by Sue Robbins | Feb 25, 2020 | Migraine
The United States Food and Drug Administration (US FDA) has just approved Vyepti™ for the preventive treatment of migraine. Vyepti (eptinezumab-jjmr) will be the first intravenous (IV) preventive treatment on the market for migraine disease. It will be available...
